Crazy Cat Lady Parasite Combined with Immunotherapy Improves Response in Some Cancers

Some tumors do not respond to the immune system and cytotoxic cells that are naturally involved in the body’s defense. In a recent study, these unresponsive “cold” tumors were treated with immunotherapy and an inactivated protozoan in a mouse model. Results showed regression of the tumors after treatment and improved survival rates in the treated mice.

Toxoplasma gondii

Toxoplasma Gondii

Read Also: Crazy Cat Lady Syndrome: Is it Love or an Infection?

Tumor cells undergo profound genetic changes and, in particular, stop expressing antigens on their surface that trigger the immune response as the disease progresses. This allows them to escape the surveillance and destruction system of cytotoxic cells. In addition, some of them can express transmembrane proteins Programmed death ligand 1 (PD-L1) that allow them to escape cytotoxic T lymphocytes by inducing their inhibition.

Unlike chemotherapy or radiation therapy, this new method of treatment does not directly attack the cancer cells but helps the immune system recognize and destroy them. In this approach, some of the tools used, such as monoclonal antibodies (anti-PDL1), have the advantage of specifically targeting tumor cells by blocking the expression of proteins that allow them to avoid immune cytotoxicity. Long-lasting therapeutic effects have recently been demonstrated using this immunotherapy against solid tumors in advanced cancers.

Toxoplasma Gondii: a useful parasite

Because there are tumors that do not respond to immunotherapy, so-called cold tumors, a group of researchers from the Universities of Nottingham (UK) and Ningbo and Shanxi (China) came up with the idea of using inactivated pathogens such as Toxoplasma Gondii to modulate the immune response in cold tumors. The idea is to enhance the therapeutic effect of monoclonal antibodies that block the escape proteins of cancer cells.

Read Also: Role of Mutated Tumor Suppressor Genes in Facilitating Cancer Cells Avoidance of the Immune System

Toxoplasma Gondii usually associated with cats (Crazy Cal Lady Syndrom) is an intracellular protozoan parasite that infects warm-blooded animals, including humans. It is found worldwide (one-third of the world’s population is considered carriers). It does not usually cause symptoms but is known to be dangerous to seronegative pregnant women (risk of fetal abnormalities) or immunocompromised individuals (cerebral toxoplasmosis). It can, if inactivated, increase immunogenicity in the tumor microenvironment and reverse tumor-related immunosuppression.

Read Also: Combination of Immunotherapy Agents Promotes Long-Term Cancer Remission in Study

In this study, using a mouse model of cancer (melanoma, lung cancer, and colon adenocarcinoma), the researchers combined intra-tumor administration of an avirulent mutant strain of Toxoplasma Gondii with anti-PDL1 immunotherapy that targets the junction between immune cells (T lymphocytes) and proteins on the surface of tumor cells. The results showed a reduction in tumor size in the different tumors studied, provided the injection site is in the tumor microenvironment. This decrease is associated with increased infiltration of inflammatory cells with a pivotal role of CD8 and NK natural killer T cells and an improvement in the survival rate of mice.

The use of immunotherapies that block immune checkpoints developed by some cancers offers new perspectives in cancer treatment. However, the efficacy of such treatment is limited to a minority of patients. By combining this treatment with an injection of inactivated Toxoplasma Gondii into tumors, this study explores new avenues in cancer treatment research.

Read Also: Mesothelioma: Immunotherapy a Potential Alternative to Chemotherapy


Synergy between Toxoplasma gondii type I ΔGRA17 immunotherapy and PD-L1 checkpoint inhibition triggers the regression of targeted and distal tumors

Articles you may like:

Study Reveals The Crucial Role Of Immunotherapy In Lung Fibrosis

Researchers Scan Single-Molecules of Peptides with Nanopore Sequencing Technology

Combination of Immunotherapy Agents Promotes Long-Term Cancer Remission in Study

Mechanism Developed to Manipulate Oxidative Stress Using Glutathione Transporter Could Destroy Cancer Cells

Hearing Loss: MIT Study Shows That COVID-19 Also Attacks Our Ears

Vaccinated People Can Still Contract and Transmit the Delta Variant According to Imperial College Study

Finnish Scientists Produce Lab-Grown Coffee That Tastes Like the Real Thing

What the Rest of the World Can Learn from the Chinese Response to the Pandemic

7 Diseases That Are Transmitted through Tick Bites That You Should Be Aware Of

Burnout Latest Facts: Causes, Risk Factors, Symptoms, Treatment and How to Protect Yourself at Work?

HGH Dosages Currently Being Used for Anti Aging, Weight Loss, and Bodybuilding

Health Insurance: Why It Is Important to Be Insured All the Time

How to Grow Taller

Chronic Pain Can Lead To Anxiety and Depression According to NeuRA Study

Giving Employees the Possibility to Take a 30 Minute Nap Improves Productivity

Global Food Security: Climate Change Is Likely to Cause More Plant Diseases Which Will Affect Crop Yield

HGH Benefits

Vaccination rates below 90% Could Paradoxically Promote the Emergence of Resistant Variants

Nightmare Scenario: Could the Current Poorly Implemented Vaccination Campaign Lead to More Deadly SARS-CoV-2 Strains

Possible Causes of the Sudden Fall In COVID-19 Infections in the UK and Europe

Moderna and Pfizer’s mRNA Vaccines Do Not Make Straight Men Gay

Gilmore Health

Coronavirus: The Real and False Side Effects of COVID-19 Vaccines


Genf20 Plus

Growth Factor Plus Reviews




Want to Stay Informed?

Join the Gilmore Health News Newsletter!

Want to live your best life?

Get the Gilmore Health Weekly newsletter for health tips, wellness updates and more.

By clicking "Subscribe," I agree to the Gilmore Health and . I also agree to receive emails from Gilmore Health and I understand that I may opt out of Gilmore Health subscriptions at any time.